Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Gantz

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Diabetic Medicine : a Journal of the British Diabetic Association|February 9, 2026
Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid populationAshish Rai, James Marshall, Sampada Nandyala, et al.
Cell Metabolism|October 3, 2006
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu, Ira Gantz, Bret Musser, et al.
Cell Metabolism|January 8, 2008
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intakeCarol Addy, Hamish Wright, Koen Van Laere, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Diabetic Medicine : a Journal of the British Diabetic Association|February 9, 2026
Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid populationAshish Rai, James Marshall, Sampada Nandyala, et al.
Cell Metabolism|October 3, 2006
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu, Ira Gantz, Bret Musser, et al.
Cell Metabolism|January 8, 2008
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intakeCarol Addy, Hamish Wright, Koen Van Laere, et al.
Pageof 7